124 related articles for article (PubMed ID: 22276607)
1. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
Wader KF; Fagerli UM; Børset M; Lydersen S; Hov H; Sundan A; Bofin A; Waage A
Histopathology; 2012 Feb; 60(3):443-51. PubMed ID: 22276607
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
3. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
4. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of hepatocyte growth factor and microvessel bone marrow density in patients with chronic myeloid leukaemia.
Zhelyazkova AG; Tonchev AB; Kolova P; Ivanova L; Gercheva L
Scand J Clin Lab Invest; 2008; 68(6):492-500. PubMed ID: 18609087
[TBL] [Abstract][Full Text] [Related]
6. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways.
Previdi S; Maroni P; Matteucci E; Broggini M; Bendinelli P; Desiderio MA
Eur J Cancer; 2010 Jun; 46(9):1679-91. PubMed ID: 20350802
[TBL] [Abstract][Full Text] [Related]
7. Expression of hepatocyte growth factor and c-met protein is significantly associated with the progression of oral squamous cell carcinoma in Taiwan.
Chen YS; Wang JT; Chang YF; Liu BY; Wang YP; Sun A; Chiang CP
J Oral Pathol Med; 2004 Apr; 33(4):209-17. PubMed ID: 15061708
[TBL] [Abstract][Full Text] [Related]
8. Autocrine and/or paracrine growth of aggressive ATLL cells caused by HGF and c-Met.
Onimaru Y; Tsukasaki K; Murata K; Imaizumi Y; Choi YL; Hasegawa H; Sugahara K; Yamada Y; Hayashi T; Nakashima M; Taguchi T; Mano H; Kamihira S; Tomonaga M
Int J Oncol; 2008 Oct; 33(4):697-703. PubMed ID: 18813782
[TBL] [Abstract][Full Text] [Related]
9. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
10. Soluble c-Met in serum of patients with multiple myeloma: correlation with clinical parameters.
Wader KF; Fagerli UM; Holt RU; Børset M; Sundan A; Waage A
Eur J Haematol; 2011 Nov; 87(5):394-9. PubMed ID: 21466586
[TBL] [Abstract][Full Text] [Related]
11. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors.
Burgess T; Coxon A; Meyer S; Sun J; Rex K; Tsuruda T; Chen Q; Ho SY; Li L; Kaufman S; McDorman K; Cattley RC; Sun J; Elliott G; Zhang K; Feng X; Jia XC; Green L; Radinsky R; Kendall R
Cancer Res; 2006 Feb; 66(3):1721-9. PubMed ID: 16452232
[TBL] [Abstract][Full Text] [Related]
12. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
Derksen PW; de Gorter DJ; Meijer HP; Bende RJ; van Dijk M; Lokhorst HM; Bloem AC; Spaargaren M; Pals ST
Leukemia; 2003 Apr; 17(4):764-74. PubMed ID: 12682635
[TBL] [Abstract][Full Text] [Related]
13. Plasma cell membrane localization of c-MET predicts longer survival in patients with malignant mesothelioma: a series of 157 cases from the MESOPATH Group.
Levallet G; Vaisse-Lesteven M; Le Stang N; Ilg AG; Brochard P; Astoul P; Pairon JC; Bergot E; Zalcman G; Galateau-Sallé F
J Thorac Oncol; 2012 Mar; 7(3):599-606. PubMed ID: 22246193
[TBL] [Abstract][Full Text] [Related]
14. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
15. Expression and localization of hepatocyte growth factor and its receptor c-Met in inverted papillomas.
Choi JH; Lee SH; Lee HM; Lee SH; Jung HH; Choi J; Lim HW; Lee SW; Kang SM
Acta Otolaryngol; 2006 Jul; 126(7):724-9. PubMed ID: 16803712
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of c-Met, its ligand HGF/SF and HER2/neu in DCIS and adjacent normal breast tissue.
Lindemann K; Resau J; Nährig J; Kort E; Leeser B; Annecke K; Welk A; Schäfer J; Vande Woude GF; Lengyel E; Harbeck N
Histopathology; 2007 Jul; 51(1):54-62. PubMed ID: 17593080
[TBL] [Abstract][Full Text] [Related]
17. Expression of hepatocyte growth factor and c-Met in hypopharyngeal squamous cell carcinoma.
Kim CH; Moon SK; Bae JH; Lee JH; Han JH; Kim K; Choi EC
Acta Otolaryngol; 2006 Jan; 126(1):88-94. PubMed ID: 16308260
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors.
Trovato M; Vitarelli E; Grosso M; Alesci S; Benvenga S; Trimarchi F; Barresi G
Eur J Histochem; 2004; 48(3):291-7. PubMed ID: 15590419
[TBL] [Abstract][Full Text] [Related]
19. Expression and localization of HGF and met in Wilms' tumours.
Alami J; Williams BR; Yeger H
J Pathol; 2002 Jan; 196(1):76-84. PubMed ID: 11748645
[TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas.
Hecht M; Papoutsi M; Tran HD; Wilting J; Schweigerer L
Cancer Res; 2004 Sep; 64(17):6109-18. PubMed ID: 15342394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
